ATE534038T1 - Neurodegenerative marker für alzheimer-krankheit - Google Patents

Neurodegenerative marker für alzheimer-krankheit

Info

Publication number
ATE534038T1
ATE534038T1 AT09013088T AT09013088T ATE534038T1 AT E534038 T1 ATE534038 T1 AT E534038T1 AT 09013088 T AT09013088 T AT 09013088T AT 09013088 T AT09013088 T AT 09013088T AT E534038 T1 ATE534038 T1 AT E534038T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
markers
neurodegenerative
values
Prior art date
Application number
AT09013088T
Other languages
English (en)
Inventor
Aye Mu Myint
Manfred Schawaller
Markus J Schwarz
Harald Hampel
Original Assignee
Univ Antwerp
Univ Maastricht
Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie
Verstappen Leopold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Antwerp, Univ Maastricht, Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie, Verstappen Leopold filed Critical Univ Antwerp
Application granted granted Critical
Publication of ATE534038T1 publication Critical patent/ATE534038T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Mushroom Cultivation (AREA)
  • Input From Keyboards Or The Like (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT09013088T 2005-04-06 2006-03-30 Neurodegenerative marker für alzheimer-krankheit ATE534038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007558 2005-04-06

Publications (1)

Publication Number Publication Date
ATE534038T1 true ATE534038T1 (de) 2011-12-15

Family

ID=36293430

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09013088T ATE534038T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für alzheimer-krankheit
AT06723873T ATE468537T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für depression.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06723873T ATE468537T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für depression.

Country Status (14)

Country Link
US (2) US20080131921A1 (de)
EP (2) EP2146209B1 (de)
JP (1) JP4958893B2 (de)
AT (2) ATE534038T1 (de)
CY (1) CY1110116T1 (de)
DE (1) DE602006014379D1 (de)
DK (2) DK1866650T3 (de)
ES (2) ES2377704T3 (de)
HK (1) HK1137219A1 (de)
NO (2) NO20075671L (de)
PL (2) PL2146209T3 (de)
PT (2) PT2146209E (de)
SI (1) SI1866650T1 (de)
WO (1) WO2006105907A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016101A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Procédé d'évaluation de stress, appareil d'évaluation de stress, système d'évaluation de stress, programme d'évaluation de stress et support d'enregistrement associé
AT9843U1 (de) * 2007-03-27 2008-04-15 Kepplinger Berthold Dr Messung von biologischen markern
BRPI0906858B8 (pt) 2008-01-18 2021-07-27 Harvard College métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer.
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
WO2009100243A2 (en) * 2008-02-05 2009-08-13 University Of Miami Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients
CN104777314B (zh) 2009-08-12 2017-01-04 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
EP2596116A4 (de) 2010-07-23 2014-03-19 Harvard College Verfahren zur erkennung von autoimmun- oder autoimmunbezogenen erkrankungen oder leiden
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20120053073A1 (en) 2010-07-23 2012-03-01 President And Fellows Of Harvard College Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids
BR112013001752A2 (pt) 2010-07-23 2016-05-31 Harvard College método de detectar doenças ou condições usando células fagocídicas
EP2778233B1 (de) 2011-11-10 2017-01-11 Human Metabolome Technologies, Inc. Verfahren zur messung von ethanolaminphosphat
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
BR112014031414A2 (pt) 2012-06-15 2017-06-27 Stylli Harry métodos de detectar doenças ou condições utilizando células doentes circulantes
US20150285805A1 (en) 2012-11-05 2015-10-08 Ospedale San Raffaele S.R.L. Biomarkers of multiple myeloma development and progression
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
EP2799878A1 (de) * 2013-05-03 2014-11-05 SALION GmbH In vitro Verfahren zur Früherkennung von potenziellen Entzündungen, insbesondere im Zusammenhang mit der Abstoßung eines Transplantats
US20160003857A1 (en) * 2014-07-02 2016-01-07 Cecil Bennett Methods and systems for detecting polypharmacy
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP3413050A1 (de) * 2017-06-08 2018-12-12 SALION GmbH In vitro verfahren zur erkennung neurodegenerativer erkrankungen
CA3077211A1 (en) * 2017-09-27 2019-04-04 University of North Carolina Wilmington Human waste water and human-derived pathogen scouting tool
KR102699211B1 (ko) 2018-03-19 2024-08-26 후지필름 가부시키가이샤 정신 질환의 판정 방법
EP3769797A4 (de) * 2018-03-22 2021-12-15 JAPAN Medical Device Technology Co., Ltd. Bioresorbierbarer stent
KR102159344B1 (ko) * 2019-08-05 2020-09-23 한국과학기술연구원 행위 중독의 진단용 조성물, 키트 및 이를 이용한 행위 중독의 진단을 위한 키누레닌의 검출 방법
US20220412908A1 (en) * 2019-11-26 2022-12-29 Kyocera Corporation Stress measurement system and stress measurement method
WO2022075354A1 (en) * 2020-10-06 2022-04-14 Okinawa Institute Of Science And Technology School Corporation A method for obtaining an index for the diagnosis of alzheimer's disease (ad)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194217B1 (en) * 1980-01-14 2001-02-27 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
JP2000131318A (ja) * 1998-10-22 2000-05-12 Nikken Foods Co Ltd 快・不快ストレス状態解析方法
EP1050758A1 (de) * 1999-05-03 2000-11-08 Evotec BioSystems AG Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Neurotrophin 3-Spiegel basiert sind
FR2827045B1 (fr) * 2001-07-05 2007-08-10 Univ Pasteur Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments
JP2004198325A (ja) * 2002-12-19 2004-07-15 Oriental Yeast Co Ltd ストレスの測定方法

Also Published As

Publication number Publication date
CY1110116T1 (el) 2015-01-14
PT2146209E (pt) 2011-12-30
PL2146209T3 (pl) 2012-05-31
ES2346467T3 (es) 2010-10-15
EP1866650A1 (de) 2007-12-19
EP2146209A1 (de) 2010-01-20
NO20075671L (no) 2007-11-06
ES2377704T3 (es) 2012-03-30
PT1866650E (pt) 2010-06-01
DK1866650T3 (da) 2010-09-06
JP4958893B2 (ja) 2012-06-20
DK2146209T3 (da) 2012-02-13
SI1866650T1 (sl) 2010-12-31
PL1866650T3 (pl) 2011-04-29
HK1137219A1 (en) 2010-07-23
NO20120452L (no) 2007-11-06
ATE468537T1 (de) 2010-06-15
US20120196300A1 (en) 2012-08-02
EP2146209B1 (de) 2011-11-16
WO2006105907A1 (en) 2006-10-12
JP2008537111A (ja) 2008-09-11
US20080131921A1 (en) 2008-06-05
DE602006014379D1 (de) 2010-07-01
EP1866650B1 (de) 2010-05-19

Similar Documents

Publication Publication Date Title
ATE534038T1 (de) Neurodegenerative marker für alzheimer-krankheit
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
CY1112737T1 (el) Ισοτοπικα σεσημασμενες ενωσεις βενζοfuran σαν παραγοντες απεικονισης για πρωτεϊνες δημιουργιας αμυλοειδους (αμυloid)
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
EP1700096A4 (de) Nachweis von proteinen und prionen mit veränderter konformation
ATE554389T1 (de) Apex als marker für lungenkrebs
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
FR2874675B1 (fr) Frein pour roue avec capteur d'usure
ATE473018T1 (de) Stöchiometrisch definierte farbstoffmarkierte substanzen zur messung der glomerulären filtrationsrate
FR2816411B1 (fr) Moyens de detection de la transformation pathologique de la proteine app et leurs applications
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
DE60324820D1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo
ATE530548T1 (de) Neue dibenzoäc,hüä1,5ü naphthyridine und ihre verwendung als dna-sonden
FR2852096B1 (fr) Instrument indicateur de direction permettant d'indiquer l'heure et la direction de la mecque.
ATE442084T1 (de) Messung des energieverbrauchs
GB0622194D0 (en) Method for diagnosing or detecting alzheimer's disease
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
WO2008148492A8 (en) Neurofilamental proteins as biomarker for alzheimer's disease
WO2008148491A8 (en) Neural cell adhesion molecule 1 as biomarker for alzheimer's disease
WO2008148493A3 (en) Annexin a5 and annexin a6 as biomarkter for alzheimer's disease